Andy leads a team of highly experienced analysts dedicated to understanding the science behind novel therapies. They focus on identifying unmet medical needs across various therapeutic areas, engaging with key opinion leaders to uncover potential breakthroughs. By prioritizing companies that address these needs, they believe there will always be demand and reimbursement, regardless of economic conditions.
